47 completed, 9 terminated, 9 unknown, 3 withdrawn. 21 Phase 3, 19 Phase 2, 17 Phase 4, 5 Not applicable, 3 Phase 1.
Follow Glatiramer Acetate: new trials by email Literature Review of Glatiramer Acetate trials Research Report on Glatiramer Acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis ofatumumab, glatiramer acetate, interferon β1 - Relapsing Multiple Sclerosis | Recruiting | Novartis Pharmaceuticals | 800 | 2022-05-10 | 2026-07-30 | |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis | Active not recruiting | Biogen | 1178 | 2021-09-24 | 2026-10-15 | |
| Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS Ofatumumab, First line DMT - Multiple Sclerosis | Phase 3 | Completed | Novartis Pharmaceuticals | 185 | 2021-07-23 | 2026-03-03 |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis | Phase 2 | Withdrawn | Biogen | 2021-06-30 | 2023-06-01 | |
| A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate - Relapsing Multiple Sclerosis (RMS) | Phase 4 | Terminated | Novartis Pharmaceuticals | 24 | 2021-06-10 | 2025-05-16 |
| Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure Copaxone, guideline directed medical therapy (GDMT) - Acute Decompensated Heart Failure, Cytokine Storm | Phase 2 | Completed | Hadassah Medical Organization | 14 | 2021-01-04 | 2023-08-22 |
| Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS). DMT - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Not applicable | Unknown | Amsterdam UMC, location VUmc | 130 | 2020-07-01 | 2020-10-19 |
| A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors Copaxone - Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma | Phase 1 | Unknown | University of Kansas Medical Center | 10 | 2019-07-26 | 2023-05-19 |
| Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Active not recruiting | The Cleveland Clinic | 800 | 2019-01-03 | 2026-08-31 |
| Czech Pharmaco-epidemiological Study on Disease Modifying Drugs interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab - Multiple Sclerosis | Completed | IMPULS Endowment Fund | 17478 | 2019-01-01 | 2023-03-09 | |
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod - Multiple Sclerosis, Relapsing-Remitting | Not applicable | Completed | Johns Hopkins University | 900 | 2018-05-02 | 2026-09-23 |
| Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients Rituximab, Glatiramer Acetate - Secondary Progressive Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Isfahan University of Medical Sciences | 84 | 2017-12-01 | 2019-05-23 |
| A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon - Multiple Sclerosis | Phase 3 | Terminated | Genzyme, a Sanofi Company | 16 | 2017-10-23 | 2026-08-04 |
| COMparison Between All immunoTherapies for Multiple Sclerosis. Rituximab - Relapsing-remitting Multiple Sclerosis | Completed | Karolinska Institutet | 3526 | 2017-06-02 | 2025-04-20 | |
| Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis" Glatiramer acetate - Multiple Sclerosis | Completed | Teva Takeda Pharma Ltd. | 1332 | 2015-11-24 | 2024-06-13 | |
| Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® Copaxone® - Multiple Sclerosis | Phase 4 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 861 | 2015-08-10 | 2021-12-09 |
| Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran Glatiramer Acetate - Relapsing Multiple Sclerosis | Completed | Cinnagen | 368 | 2015-04-12 | 2021-06-16 | |
| An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome Glatiramer Acetate (Copaxone®) - Rett Syndrome | Phase 1 | Unknown | Sheba Medical Center | 10 | 2014-01-01 | 2014-02-04 |
| Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 255 | 2013-10-01 | 2016-05-11 |
Showing 20 of 73. Sign in to see all of them.
Multiple Sclerosis (37) · Multiple Sclerosis, Relapsing-Remitting (31) · Recurrence (4) · Autoimmune Diseases (2) · Multiple Sclerosis, Chronic Progressive (2) · Rett Syndrome (2) · Amyotrophic Lateral Sclerosis (1) · Bone Diseases, Metabolic (1) · COVID-19 (1) · Carcinoma, Basal Cell (1) · Carcinoma, Squamous Cell (1) · Coronavirus Infections (1) · Crohn Disease (1) · Cytokine Release Syndrome (1) · Diabetic Retinopathy (1)
Teva Branded Pharmaceutical Products R&D, Inc. (17) · Novartis Pharmaceuticals (7) · Biogen (5) · Teva Neuroscience, Inc. (4) · Sanofi (3) · EMD Serono (2) · Johns Hopkins University (2) · Sheba Medical Center (2) · Amphia Hospital (1) · Amsterdam UMC, location VUmc (1) · Bayer (1) · Biocad (1) · Cinnagen (1) · Federal University of São Paulo (1) · Fred Lublin (1)
United States (36) · Italy (13) · Germany (12) · Canada (9) · France (9) · Israel (9) · Poland (9) · Russia (9) · Spain (9) · United Kingdom (9) · Czechia (7) · Croatia (6) · Mexico (6) · Ukraine (6) · Austria (5)
Jean Godin, MD (2) · MerriKay Oleen-Burkey, Ph.D. (2) · Tom Smith, MD (2) · Abdorreza Naser Moghadasi, Assistant Professor (1) · Alexey Boyko, MD (1) · Anat Achiron, MD, PhD (1) · Anders Svenningsson, MD, PhD (1) · Andreea Nissenkorn, Dr. (1) · Anna Fogdell-Hahn, PhD (1) · Anne Cross, M.D. (1) · Annette Langer-Gould, MD, PhD (1)
PMID 28607708, PMID 18789766, PMID 19279320, PMID 19687024, PMID 19729344, PMID 19776092, PMID 19815268, PMID 20837847, PMID 21111490, PMID 22622860, PMID 22992072, PMID 23424159, PMID 23647445, PMID 24131282, PMID 24624979, PMID 24686106, PMID 25424122, PMID 25787057, PMID 26049148, PMID 26195058, PMID 26265273, PMID 26265274, PMID 26458034, PMID 26526385, PMID 26621682, PMID 26932146, PMID 27363291, PMID 27503905, PMID 27733070, PMID 28724581, PMID 28751099, PMID 28770420, PMID 30635477, PMID 30918100, PMID 31132664, PMID 31289819, PMID 32426039, PMID 32554770, PMID 32852530, PMID 34376508, PMID 34433679, PMID 34695274, PMID 34759712, PMID 34927308, PMID 36382118, PMID 37061656, PMID 37119208, PMID 37830451, PMID 38648580, PMID 38654416
2009 (1), 2015 (1), 2016 (1), 2019 (1), R01NS051591 (1), U01NS045719 (1)